ECSP034922A - PIRROLOPIRIMIDINES - Google Patents

PIRROLOPIRIMIDINES

Info

Publication number
ECSP034922A
ECSP034922A EC2003004922A ECSP034922A ECSP034922A EC SP034922 A ECSP034922 A EC SP034922A EC 2003004922 A EC2003004922 A EC 2003004922A EC SP034922 A ECSP034922 A EC SP034922A EC SP034922 A ECSP034922 A EC SP034922A
Authority
EC
Ecuador
Prior art keywords
compounds
bioisoesters
prodrugs
solvates
oxides
Prior art date
Application number
EC2003004922A
Other languages
Spanish (es)
Inventor
Michael Louis Edwards
David John Aldous
Paul Joseph Cox
Franck Halley
Tahir Nadeem Majid
Shelley Amendola
Stephanie Daniele Deprets
Brian Leslie Pedgrift
Iain Mcfarlane Mclay
Christopher Edlin
Bernard Baudoin
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ECSP034922A publication Critical patent/ECSP034922A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

A N-óxidos, profármacos, bioisoésteres ácidos, sales farmacéuticamente aceptables o solvatos de tales compuestos, ó N-óxidos, profármacos, ó bioisoésteres ácidos de tales sales ó solvatos; a composiciones que comprenden tales compuestos; y a métodos de tratamiento que comprenden administrar, a un paciente que lo necesite, tales compuestos y composicionesA N-oxides, prodrugs, acid bioisoesters, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisoesters of such salts or solvates; to compositions comprising such compounds; and to treatment methods comprising administering such compounds and compositions to a patient in need.

EC2003004922A 2001-06-23 2003-12-23 PIRROLOPIRIMIDINES ECSP034922A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds

Publications (1)

Publication Number Publication Date
ECSP034922A true ECSP034922A (en) 2004-04-28

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004922A ECSP034922A (en) 2001-06-23 2003-12-23 PIRROLOPIRIMIDINES

Country Status (22)

Country Link
EP (1) EP1404676A1 (en)
JP (1) JP4344607B2 (en)
CN (1) CN1294135C (en)
AU (1) AU2002314325B8 (en)
BR (1) BR0210652A (en)
CA (1) CA2451932C (en)
CZ (1) CZ20033443A3 (en)
EA (1) EA007415B1 (en)
EC (1) ECSP034922A (en)
EE (1) EE05432B1 (en)
GB (1) GB0115393D0 (en)
HU (1) HUP0400300A3 (en)
ME (1) MEP19308A (en)
NZ (1) NZ529766A (en)
OA (1) OA12632A (en)
PL (1) PL374096A1 (en)
RS (1) RS51698B (en)
SK (1) SK15882003A3 (en)
TN (1) TNSN03144A1 (en)
TR (1) TR200302242T2 (en)
UA (1) UA76760C2 (en)
WO (1) WO2003000695A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
JP2007511596A (en) * 2003-11-17 2007-05-10 ファイザー・プロダクツ・インク Pyrrolopyrimidine compounds useful in the treatment of cancer
WO2005051393A1 (en) * 2003-11-25 2005-06-09 Pfizer Products Inc. Method of treatment of atherosclerosis
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
FR2876103B1 (en) * 2004-10-01 2008-02-22 Aventis Pharma Sa NOVEL BIS-AZAINDOL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
DE602005023333D1 (en) 2004-10-15 2010-10-14 Takeda Pharmaceutical KINASE INHIBITORS
FR2878849B1 (en) 2004-12-06 2008-09-12 Aventis Pharma Sa SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN103214484B (en) 2005-12-13 2016-07-06 因塞特控股公司 Pyrrolo-[2,3-b] pyridine replaced as the heteroaryl of Janus inhibitors of kinases and pyrrolo-[2,3-b] pyrimidine
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CA2711777A1 (en) 2008-01-11 2009-08-13 Natco Pharma Limited Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer drugs
UA106045C2 (en) 2008-06-10 2014-07-25 Еббві Інк. Tricyclic compounds
HUE046493T2 (en) 2009-05-22 2020-03-30 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc Heteroaryl btk inhibitors
CN102711476B (en) 2009-12-01 2014-12-03 Abbvie公司 Novel tricyclic compounds
MY175156A (en) 2010-03-10 2020-06-11 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
TWI499421B (en) 2010-05-21 2015-09-11 Incyte Corp Topical formulation for a jak inhibitor
JP5917544B2 (en) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103415515B (en) 2010-11-19 2015-08-26 因塞特公司 The pyrrolopyridine replaced as the cyclobutyl of JAK inhibitor and Pyrrolopyrimidine derivatives
CN103476776B (en) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 2,4-diaminourea-6,7-dihydro-5H-pyrrolo-[2,3] pyrimidine derivatives as FAK/Pyk2 inhibitor
CN102093364B (en) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor
AU2012273164B2 (en) 2011-06-20 2015-05-28 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
CA2869954C (en) 2012-04-20 2023-01-03 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9127003B2 (en) 2012-07-26 2015-09-08 Glaxo Group Limited 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors
ES2889757T3 (en) * 2012-09-06 2022-01-13 Plexxikon Inc Compounds and methods for the modulation of kinases and indications for these
WO2014078486A1 (en) 2012-11-15 2014-05-22 Incyte Corporation Sustained-release dosage forms of ruxolitinib
ES2707355T3 (en) 2013-03-06 2019-04-03 Incyte Holdings Corp Processes and intermediate products to elaborate a JAK inhibitor
CA2901334A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
CA2901929A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
AU2014234077A1 (en) 2013-03-14 2015-10-01 Abbvie Inc. Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors
TW201444836A (en) 2013-03-14 2014-12-01 Abbvie Inc Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
EP2970299A1 (en) * 2013-03-14 2016-01-20 Abbvie Inc. Pyrrolopyrimindine cdk9 kinase inhibitors
CA3155500A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
CN104804001B9 (en) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-substituted pyrrolo [2,3-d ] pyrimidine compounds and uses thereof
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116270645A (en) 2015-10-16 2023-06-23 艾伯维公司 Process for preparing imidazo [1,2-a ] pyrrolo [2,3-e ] pyrazines and solid forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
JP2020510016A (en) 2017-03-09 2020-04-02 アッヴィ・インコーポレイテッド Methods for treating Crohn's disease and ulcerative colitis
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
MA51771B1 (en) 2018-01-30 2022-03-31 Incyte Corp Processes for the preparation of (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidin-4-one)
PE20210402A1 (en) 2018-03-30 2021-03-02 Incyte Corp TREATMENT OF SUPURATIVE HYDRADENITIS USING JAK INHIBITORS
JP2022508648A (en) 2018-10-05 2022-01-19 アンナプルナ バイオ インコーポレイテッド Compounds and compositions for treating conditions associated with APJ receptor activity
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69712745T2 (en) * 1996-01-23 2002-10-31 Novartis Ag PYRROLOPYRIMIDINES AND METHOD FOR THE PRODUCTION THEREOF
US6413971B1 (en) * 1996-11-27 2002-07-02 Pfizer Inc Fused bicyclic pyrimidine derivatives
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
PT1087970E (en) * 1998-06-19 2004-06-30 Pfizer Prod Inc PYRIMIDINE COMPOUNDS 2,3-D | PYRIMIDINE
NZ510587A (en) * 1998-09-18 2003-11-28 Abbott Gmbh & Co 4-aminopyrrolopyrimidines as kinase inhibitors
CZ303875B6 (en) * 1999-12-10 2013-06-05 Pfizer Products Inc. Pyrrolo [2,3-d]pyrimidine compound and pharmaceutical composition in which the compound is comprised

Also Published As

Publication number Publication date
UA76760C2 (en) 2006-09-15
CN1294135C (en) 2007-01-10
CN1518552A (en) 2004-08-04
EE200400003A (en) 2004-02-16
RS51698B (en) 2011-10-31
JP4344607B2 (en) 2009-10-14
PL374096A1 (en) 2005-09-19
EA200400073A1 (en) 2004-08-26
NZ529766A (en) 2008-11-28
RS99203A (en) 2006-12-15
TR200302242T2 (en) 2004-12-21
BR0210652A (en) 2004-08-10
HUP0400300A2 (en) 2007-08-28
EP1404676A1 (en) 2004-04-07
GB0115393D0 (en) 2001-08-15
EE05432B1 (en) 2011-06-15
AU2002314325B2 (en) 2009-01-08
TNSN03144A1 (en) 2005-12-23
MEP19308A (en) 2010-06-10
WO2003000695A1 (en) 2003-01-03
HUP0400300A3 (en) 2010-12-28
JP2005508300A (en) 2005-03-31
SK15882003A3 (en) 2004-07-07
CA2451932C (en) 2009-12-29
OA12632A (en) 2006-06-14
EA007415B1 (en) 2006-10-27
AU2002314325B8 (en) 2009-01-29
CA2451932A1 (en) 2003-01-03
WO2003000695A8 (en) 2004-03-11
CZ20033443A3 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
ECSP034922A (en) PIRROLOPIRIMIDINES
DK1346041T3 (en) Therapeutic agents and methods for their use in the treatment of an amyloidogenic disease
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
CR7193A (en) PIRROLOPIRIMIDINAS AS INHIBITORS OF THE KINASA PROTENINE
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
SE0001899D0 (en) New compounds
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
MXPA04004842A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
MXPA04004837A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TNSN06034A1 (en) Pyridazine derivatives and their use as therapeutic agents
HUP0202570A1 (en) Compositions and therapeutic methods involving isoflavones and analogues thereof
EE05419B1 (en) Substituted oxazolidinones for combination therapy
NO20050807L (en) Pharmaceutical compositions including dextromethorphan and quinidine for the treatment of neurological disorders
TNSN05265A1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
GB0002336D0 (en) Medicaments
GB0130677D0 (en) Medicaments and novel compounds
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA02010316A (en) Compositions and therapies for hyperlipidaemia associated disorders.
MXPA04011835A (en) Treatment for depression and anxiety by the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent.
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA06007007A (en) Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours.